605116.SHG Aurisco Pharmaceutical Co Ltd
- Market cap
- CNY 7.63B
- P/E
- 24.4x
- P/B
- 2.70x
- ROE
- 11.9%
- Dividend yield
- 1.63%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 605116.SHG undervalued?
Graham number605116.SHG trades 71.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aurisco Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Aurisco Pharmaceutical Co Ltd yet.
Aurisco Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aurisco Pharmaceutical Co Ltd
Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for …
Full company profileAurisco Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aurisco Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 590M | 544M | 575M | 582M | 721M | 803M | 1.01B | 1.26B | 1.48B | 1.70B | 1.66B |
| Gross Profit | 305M | 264M | 272M | 298M | 340M | 395M | 513M | 698M | 844M | 1.01B | 909M |
| Operating Income | 112M | 70.1M | 165M | 171M | 187M | 194M | 241M | 331M | 410M | 559M | 444M |
| EBITDA | 119M | 77.9M | 172M | 235M | 218M | 245M | 307M | 407M | 506M | 679M | 405M |
| Net Income | 86.7M | 44.7M | 137M | 186M | 157M | 169M | 211M | 289M | 355M | 449M | 317M |
| EPS | 1.64 | 0.12 | 0.38 | 0.52 | 0.42 | 0.42 | 0.52 | 0.71 | 0.89 | 1.11 | 0.78 |
| Balance Sheet | |||||||||||
| Total Assets | 782M | 816M | 921M | 1.10B | 1.53B | 1.72B | 2.03B | 2.57B | 3.88B | 4.22B | 4.17B |
| Total Liabilities | 192M | 132M | 133M | 123M | 148M | 213M | 349M | 607M | 1.55B | 1.56B | 1.50B |
| Shareholders' Equity | 552M | 684M | 788M | 977M | 1.39B | 1.51B | 1.68B | 1.97B | 2.33B | 2.66B | 2.68B |
| Cash & Short-term Investments | 184M | 213M | 181M | 265M | 564M | 445M | 392M | 546M | 1.07B | 792M | 641M |
| Total Debt | 48.0M | 21.0M | 9.06M | 6.77M | 12.6M | 18.0M | 52.7M | 117M | 942M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 188M | 118M | 110M | 180M | 214M | 202M | 166M | 386M | 332M | 421M | - |
| Capital Expenditure | 53.7M | 107M | 94.1M | 72.5M | 159M | 251M | 216M | 305M | 540M | 350M | 370M |
| Free Cash Flow | 135M | 11.3M | 15.6M | 107M | 55.7M | -49.0M | -49.8M | 80.1M | -208M | 71.4M | 45.7M |
| Ratios | |||||||||||
| ROE | 15.7% | 6.5% | 17.4% | 19.0% | 11.4% | 11.2% | 12.6% | 14.7% | 15.2% | 16.9% | 11.9% |
| ROA | 11.1% | 5.5% | 14.9% | 16.9% | 10.3% | 9.8% | 10.4% | 11.2% | 9.2% | 10.6% | 7.6% |
| Net Profit Margin | 14.7% | 8.2% | 23.8% | 32.0% | 21.8% | 21.0% | 20.9% | 22.9% | 24.0% | 26.5% | 19.2% |
| Debt to Equity | 0.09x | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.03x | 0.06x | 0.40x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aurisco Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.63%
- Forward dividend
- 0.34 CNY
- Payout ratio
- 27.6%
- Ex-dividend date
- Jun 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 124M | 0.31 | 27.6% |
| 2024 | CNY 94.8M | 0.24 | 26.7% |
| 2023 | CNY 65.0M | 0.16 | 22.5% |
| 2022 | CNY 52.1M | 0.13 | 24.7% |
| 2021 | CNY 48.1M | 0.12 | 28.5% |
| 2020 | CNY 36.0M | 0.10 | 22.9% |
| 2019 | - | - | - |
| 2018 | 36.0M | 0.10 | 26.3% |
| 2017 | 58.4M | 0.16 | 130.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Aurisco Pharmaceutical Co Ltd
- Insiders 78.98%
- Institutions 0.99%
- Public & others 20.04%
- Shares outstanding 406M
- Free float 93.5M
Aurisco Pharmaceutical Co Ltd company profile
- Company name
- Aurisco Pharmaceutical Co Ltd
- Ticker
- 605116.SHG
- ISIN
- CNE1000042S4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,026
- Fiscal year end
- December
- Address
- Badu Industrial Park Zone, Tiantai, China, 317200
- Phone
- 86 576 8317 0900
- Website
- aurisco.com
About Aurisco Pharmaceutical Co Ltd
Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides eplerenone, an API to treat cardiovascular diseases, lowering blood pressure, and treating heart failure; futicasone propionate, used for the treatment of asthma, respiratory tract diseases, and rhinitis; Tenofovir, an anti-infection used to treat AIDS and hepatitis B; pregabalin for the treatment of anti-epileptic, analgesic, and anti-anxiety purposes, as well as for neuralgia; abiraterone acetate to treat prostate cancer; and dydrogesterone, to treat endogenous for women's heath. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.
Aurisco Pharmaceutical Co Ltd management
8- Mr. Dingjun ChuGM & Director · born 1973
- Ms. Xiuyu WangDeputy GM, Accounting Supervisor & Financial Director · born 1981
- Ms. Liqin ZhangDeputy GM & Director of Sales · born 1976
- Mr. Guoping WangDeputy GM & Director · born 1966
- Ms. Fangfang LiBoard Secretary · born 1972
- Mr. Zhenping ZhaoDeputy General Manager · born 1973
- Ms. Mingyan XinDeputy General Manager · born 1969
- Mr. Jieming ChenDeputy General Manager · born 1974